Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Systemic Sclerosis clinical trials
Every US clinical trial registered for Systemic Sclerosis — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
27 US clinical trials · 12 currently recruiting
The research picture
Systemic Sclerosis has 27 registered US clinical trials, 12 of them open to new participants right now — about 44% of the total.
- 12
- recruiting participants now
- 44%
- of trials open to enrollment
- 3
- in Phase 3–4 (later-stage)
- 2
- top sponsor: Sanofi
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
New Orleans Pulmonary Hypertension Biobank
Louisiana State University Health Sciences Center in New Orleans
NCT03269630
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT05869955
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Nkarta
NCT06733935
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
CRISPR Therapeutics
NCT06925542
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
The University of Texas Health Science Center, Houston
NCT05989763
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Allogene Therapeutics
NCT07085104
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
M.D. Anderson Cancer Center
NCT06434363
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Hospital for Special Surgery, New York
NCT03844061
A Study of AZD0120 in Autoimmune Diseases
AstraZeneca
NCT07295847
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
Stephan Grupp MD PhD
NCT05029336
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Cabaletta Bio
NCT06328777
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Paul Szabolcs
NCT03630211
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
AstraZeneca
NCT05925803
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
Brigham and Women's Hospital
NCT05715463
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
Synthekine
NCT06544330
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Kyverna Therapeutics
NCT06400303
Scleroderma Registry
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00074568
Oral Health and People With Systemic Sclerosis
University of Alabama at Birmingham
NCT01817361
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Sanofi
NCT02921971
Psychological Treatments for Scleroderma
Johns Hopkins University
NCT00007267
Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
Genentech
NCT01933334
Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis
University of Michigan
NCT03482219
Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Sanofi
NCT01651143
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Johns Hopkins University
NCT01042158
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Hospital for Special Surgery, New York
NCT01670565
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
University of California, Los Angeles
NCT01051960
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
Northwestern University
NCT03438032
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 8 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Systemic Sclerosis Trial Landscape
ClinicalTrials.gov lists 27 US studies indexed under Systemic Sclerosis, and 12 of those are currently open to recruitment — roughly 44% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Systemic Sclerosis shows 3 late-stage studies (Phase 3 and Phase 4 combined) alongside 17 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Systemic Sclerosis is led by Sanofi with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 27 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Systemic Sclerosis?
PlainTrial tracks 27 US clinical trials for Systemic Sclerosis, of which 12 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Systemic Sclerosis?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.